Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells

Cancer Gene Therapy

Volumn 7, Issue 2, 2000, Pages 300-307

  Osaki, Shin ichi ^a   Nakanishi, Yoichi ^a   Takayama, Koichi ^a   Pei, Xin Hai ^a   Ueno, Hikaru ^b   Kara, Nobuyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Adenoviral vector; Anticancer drug; Chemosensitivity; Lung cancer; p53 gene

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AMRUBICIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; IRINOTECAN; PACLITAXEL; PROTEIN P53; VINDESINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ANIMALIA; MUS MUSCULUS;

EID: 0034072882     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700096     Document Type: Article

References (39)

1. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 1992;255:459-462.
2. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth, JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 1994;54: 2287-2291.
3. Kimura M, Tagawa M, Takenaga K, et al. Inability to induce the alteration of tumorigenicity and chemosensitivity of p53-null human pancreatic carcinoma cells after the transduction of wild-type p53 gene. Anticancer Res. 1997; 17:879-883.
4. Phelps RM, Johnson BE, Ihde DC, et al. NCI-Navy Medical Oncology Branch cell line database. J Cell Biochem Suppl. 1996;24:32-91.
5. 5 may predict the susceptibility to adenovirus-mediated gene transfer in human lung cancer. Gene Ther. 1998;5:361-368.
6. Miyake S, Makimura M, Kanegae Y, et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci USA. 1996; 93:1320-1324.
7. Ueno H, Li J-J, Tomita H, et al. Quantitative analysis of repeated adenovirus-mediated gene transfer into injured canine femoral arteries. Arterioscler Thromb Vase Biol. 1995;15:2246-2253.
8. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991;108:193-200.
9. Li JJ, Ueno H, Pan Y, et al. Percutaneous transluminal gene transfer into canine myocardium in vivo by replication-defective adenovirus. Cardiovasc Res. 1995;30:97-105.
10. Li JJ, Ueno H, Tomita H, et al. Adenovirus-mediated arterial gene transfer does not require prior injury for submaximal gene expression. Gene Ther. 1995;2:351-354.
11. Yamamoto H, Ueno H, Ooshima A, Takeshita A. Adenovirus-mediated transfer of a truncated transforming growth factor-β (TGF-β) type II receptor completely and specifically abolishes diverse signaling by TGF-β in vascular wall cells in primary culture. J Biol Chem. 1996;271: 16253-16259.
12. Scudiero DA, Shoemaker RH, Paull KD, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988;48:4827-4933.
13. Stevens MG, Olsen SC. Comparative analysis of using MTT and XTT in colorimetric assays for quantitating bovine neutrophil bactericidal activity. J Immunol Methods. 1993;157:225-231.
14. Stein U, Walther W, Shoemaker RH. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst. 1996;88: 1383-1392.
15. Kano Y, Suzuki K, Akutsu M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer. 1992;50:604-610.
16. Pei XH, Nakanishi Y, Takayama K, et al. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anticancer Drugs. 1997;8:231-237.
17. Kano Y, Ohnuma T, Okano T, Holland JF. Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res. 1988;48:351-356.
18. 2/M arrest and apoptosis. Nat Med. 1996;2:72-79.
19. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 1996;56:892-898.
20. Wu GS, El-Diery WS. p53 and chemosensitivity. Nat Med. 1996;2:255-256.
21. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957-967.
22. Kawasaki M, Nakanishi Y, Kuwano K, Yatsunami J, Takayama K, Hara N. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. Clin Cancer Res. 1997;3:1195-1200.
23. Kawasaki M, Nakanishi Y, Kuwano K, Takayama K, Kiyohara C, Hara N. Immunohistochemically detected p53 and p-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer. 1998;34:1352-1357.
24. McCurrach ME, Connor TM, Knudson CM, Korsmeyer SJ, Lowe SW. Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA. 1997;94:2345-2349.
25. Takano H, Kohno K, Matsuo K, Matsuda T, Kuwano M. DNA topoisomerase-targeting anticancer agents and drug resistance. Anticancer Drugs. 1992:323-330.
26. Gobert C, Bracco L, Rossi F, et al. Modulation of DNA topoisomerase I activity by p53. Biochemistry. 1996;35: 5778-5786.
27. Albor A, Kaku S, Kulesz MM. Wild-type and mutant forms of p53 activate human topoisomerase I: a possible mechanism for gain of function in mutants. Cancer Res. 1998;58:2091-2094.
28. Berger SH, Hakala MT. Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil. Mol Pharmacol. 1984;25:303-309.
29. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res. 1982;42:450-456.
30. Washtien WL. Thymidylate synthetase levels as a factor in 5-fluorodeoxyuridine and methotrexate cytotoxicity in gas-trointestinal tumor cells. Mol Pharmacol. 1982;21:723-728.
31. Chu E, Drake JC, Koeller DM, et al. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol. 1991;39:136-143.
32. Lee Y, Chen Y, Chang LS, Johnson LF. Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein. Exp Cell Res. 1997;234: 270-276.
33. Pritchard DM, Watson AJ, Potten CS, Jackman AL, Hickman JA. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc Natl Acad Sci USA. 1997;94:1795-1799.
34. Levine AJ, Zambetti GP. A comparison of the biological activities of wild-type and mutant p53. FASEB J. 1993;7: 855-865.
35. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-4878.
36. Kimura Y, Furuhata T, Shiratsuchi T, et al. GML sensitizes cancer cells to Taxol by induction of apoptosis. Oncogene. 1997;15:1369-1374.
37. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell. 1994; 79:329-339.
38. Smith ML, Kontny HU, Bortnick R, Fornace A Jr. The p53-regulated cyclin G gene promotes cell growth: p53 downstream effectors cyclin G and Gadd45 exert different effects on cisplatin chemosensitivity. Exp Cell Res. 1997; 230:61-68.
39. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 1993;362:849-852.